TITLE

Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?

AUTHOR(S)
Falck, Anna-Karin; Fernö, Mårten; Bendahl, Pär-Ola; Rydén, Lisa
PUB. DATE
July 2010
SOURCE
World Journal of Surgery;Jul2010, Vol. 34 Issue 7, p1434
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Prognostic and treatment-predictive biomarkers in primary breast cancer are routinely analyzed in the primary tumor, whereas metastatic tumor cells in lymph node metastases are not characterized. The present study aimed to define the concordance between biomarkers in matched pairs of breast cancers and lymph node metastases and to relate their expression to clinical outcome. Patients with primary breast cancer treated with adjuvant tamoxifen for 2 years were included. A tissue microarray of primary tumors and lymph node metastases was constructed, and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 were analyzed immunohistochemically in 262, 257, 104, and 101 patients, respectively. Five years’ distant disease-free survival (DDFS) was used as the primary end point. The concordance for biomarker expression in primary tumors and corresponding lymph node metastases was 93% for ER, 84% for PR, 97% for HER2, and 85% for Ki67. The discordant cases for HER2 status were all negative in the tumor but positive in the node. ER positivity was a significant independent predictor of improved 5-year DDFS when analyzed in the primary tumor as well as in the lymph node metastases. Ki67 positivity analyzed in both locations correlated with shortened DDFS. HER2 positivity at both locations was an indicator of early relapse. The concordance for the biomarkers analyzed in matched pairs of primary tumors and lymph node metastases was high. Moreover, survival analyses showed that the expression of biomarkers in lymph node metastases can provide prognostic information when no analyses of the primary tumor can be done. Treatment selection based on biomarkers in the lymph node is a topic for further studies.
ACCESSION #
51880525

 

Related Articles

  • Outcome of non-metastatic male breast cancer: 118 patients. Arslan, Ülkü; Öksüzoğlu, Berna; Özdemir, Nuriye; Aksoy, Sercan; Alkış, Necati; Gök, Ayşe; Kaplan, Mehmet; Gümüş, Mahmut; Berk, Veli; Uncu, Doğan; Baykara, Meltem; Çolak, Dilşen; Üyetürk, Ümmügül; Türker, İbrahim; Işıkdoğan, Abdurrahman // Medical Oncology;Jun2012, Vol. 29 Issue 2, p554 

    Studies concerning adjuvant systemic therapy and prognosis in male breast carcinoma (MBC) are limited. We aimed to evaluate outcome of the changing practices of adjuvant systemic treatment and survival in operable MBC patients over the last two decades. The medical records of 148 MBC patients...

  • Vascular Invasion in Triple-Negative Carcinoma of the Breast Identified by Endothelial Lymphatic and Blood Vessel Markers. Kuroda, Hajime; Nakai, Maki; Ohnisi, Kiyoshi; Ishida, Takafumi; Kuroda, Mina; Itoyama, Shinji // International Journal of Surgical Pathology;10/01/2010, Vol. 18 Issue 5, p324 

    The aim of this study was to determine lymph vessel invasion (LVI) and blood vessel invasion (BVI) using established biological markers and clinicopathological findings for triple-negative breast carcinoma. We reviewed all 202 cases of primary breast carcinoma that were surgically resected at...

  • Correlation of ER, PR, HER- 2 and P53 Immunoreactions with Clinico-Pathological Features in Breast Cancer. Abdollahi, Alireza; Sheikhbahaei, Sara; Safinejad, Somaye; Jahanzad, Issa // Iranian Journal of Pathology;Summer2013, Vol. 8 Issue 3, p147 

    Background and Objectives: The most prevalent malignancy among women is known to be breast cancer (BC). Several factors contribute to determining tumor prognosis and treatment strategies. In this study, the frequency and relevance of these factors are discussed. Materials and Methods: This...

  • Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer. Hannouf, Malek; Xie, Bin; Brackstone, Muriel; Zaric, Gregory // PharmacoEconomics;Feb2014, Vol. 32 Issue 2, p135 

    Background: A 21-gene recurrence score (RS) assay provides a method of guiding treatment decisions in women with early-stage breast cancer (ESBC). We investigated the cost effectiveness of using the RS assay versus current clinical practice (CCP) in post-menopausal women with estrogen- or...

  • User-friendly tool can predict risk of breast Ca metastasis.  // Contemporary OB/GYN;Oct2007, Vol. 52 Issue 10, p18 

    This article discusses a report that appeared in the August 20, 2007 issue of the "Journal of Clinical Oncology," which revealed that the use of nomogram can help answer the questions of newly diagnosed breast cancer patients about their patient-specific likelihood of developing sentinel lymph...

  • Intraductal papilloma of ectopic breast tissue in axillary lymph node of a patient with a previous intraductal papilloma of ipsilateral breast: a case report and review of the literature. Dzodic, Radan; Stanojevic, Boban; Saenko, Vladimir; Nakashima, Masahiro; Markovic, Ivan; Pupic, Gordana; Buta, Marko; Inic, Momcilo; Rogounovitch, Tatiana; Yamashita, Shunichi // Diagnostic Pathology;2010, Vol. 5, p17 

    The presence of ectopic breast tissue in axillary lymph nodes (ALN) is a benign condition that must be differentiated from primary or metastatic carcinoma. Here we report a patient who underwent excision of enlarged ALN 10 years after she had received surgical treatment of ipsilateral breast for...

  • Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. Erbes, Thalia; Orlowska-Volk, Marzenna; zur Hausen, Axel; Rücker, Gerta; Mayer, Sebastian; Voigt, Matthias; Farthmann, Juliane; Iborra, Severine; Hirschfeld, Marc; Meyer, Philipp T.; Gitsch, Gerald; Stickeler, Elmar // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Neoadjuvant chemotherapy (NC) is an established therapy in breast cancer, able to downstage positive axillary lymph nodes, but might hamper their detectibility. Even if clinical observations suggest lower lymph node yield (LNY) after NC, data are inconclusive and it is unclear whether...

  • Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial. Giuliano, Armando E.; Hunt, Kelly K.; Ballman, Karla V.; Beitsch, Peter D.; Whitworth, Pat W.; Blumencranz, Peter W.; Leitch, A. Marilyn; Saha, Sukamal; McCall, Linda M.; Morrow, Monica // JAMA: Journal of the American Medical Association;2/9/2011, Vol. 305 Issue 6, p569 

    The article discusses a study which examined the effects of complete axillary lymph node dissection (ALND) on survival of patients with sentinel lymph node (SLN) metastasis of breast cancer. All women patients included in the study underwent lumpectomy and tangential whole-breast irradiation....

  • Synoptic Reporting on Breast Cancer Biomarkers: A Novel Quality Improvement Module. Nofech-Mozes, Sharon; Jorden, Tanya; Hanna, Wedad M.; Khalifa, Mahmoud A. // Canadian Journal of Pathology;2011, Vol. 3 Issue 4, p11 

    Currently, testing for biomarkers such as estrogen receptor, progesterone receptor, and HER2/neu is undertaken in all newly diagnosed cases of invasive breast cancer. Reports of biomarker test results in synoptic format may be linked to the initial surgical pathology report through the creation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics